ArticleMolecular and clinical oncology2021

Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study.

Yukio Kadokawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.